Internal Medicine, Pulmonary Disease · Indianapolis, IN
NPI
1700923752
Since 2007
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1701 N Senate Blvd
Indianapolis, IN, 46202
Phone (888) 484-3258
Groups this clinician bills Medicare through
Medicare paid, 2024
$12K
185 services
Medicare patients, 2024
99
Average age 65
Drug cost, 2024
$3.7M
1,012 prescriptions
Company payments, 2025
$171
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Cynthia D Brown was code 99213 (office e&m - established), 54 times for 42 patients. In total Cynthia D Brown billed 185 services in 14 codes, and Medicare paid $12K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 54 | 42 | $45.87 | $2,477 |
| 99214 Office E&M - Established | Facility | 53 | 35 | $58.95 | $3,125 |
| 99232 Hospital E&M - Subsequent | Facility | 35 | 16 | $57.65 | $2,018 |
By year: 2022 $21K for 310 services; 2023 $15K for 225 services; 2024 $12K for 185 services.
Medicare prescription drug claims, 2024
In 2024, the drug Cynthia D Brown prescribed most often to Medicare patients was Azithromycin, with 107 prescriptions and refills. In total Cynthia D Brown wrote 1,012 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azithromycin Generic | 107 | 142 | 23 | $1,254 |
| Trikafta Elexacaftor/Tezacaftor/Ivacaft | 105 | 106 | 16 | $2.8M |
| Albuterol Sulfate Hfa Albuterol Sulfate | 88 | 130 | 28 | $2,518 |
| Montelukast Sodium Generic | 68 | 178 | 20 | $1,317 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 56 | 76 | 13 | $7,329 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 48 | 80 | 14 | $51K |
| Pertzye Lipase/Protease/Amylase | 32 | 40 | Under 11 | $153K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 31 | 37 | Under 11 | $3,799 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 31 | 45 | Under 11 | $7,355 |
| Prednisone Generic | 23 | 30 | 14 | $47.6 |
| Breo Ellipta Fluticasone/Vilanterol | 23 | 27 | Under 11 | $10K |
| Creon Lipase/Protease/Amylase | 21 | 21 | Under 11 | $105K |
| Zenpep Lipase/Protease/Amylase | 20 | 20 | Under 11 | $112K |
| Omeprazole Generic | 16 | 46 | Under 11 | $98.17 |
| Dupixent Pen Dupilumab | 16 | 16 | Under 11 | $57K |
Brand drugs: - claims; generic drugs: 510 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Cynthia D Brown $171 ($171 in general payments such as food, travel and fees) from 2 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $105.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $105 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $66.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.